Clinical trials: Pathological Complete Response
High-Grade Osteosarcoma
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea.
- Trial name
- NCT07878364
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- MedPacto, Inc.
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Aspergillosis
Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples
Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients (pts) with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain…
- Trial name
- NCT01430663
- Where
- 9 sites in Austria, Germany
- Volunteers
- 87 people
- Sponsor
- Heidelberg University
Preterm Infant, Early-Onset Neonatal Sepsis
Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants
This study evaluates the utility of placental/umbilical cord blood (PUCB) to perform the baseline workup testing for EONS in Very Low Birth Weight Infants: CBC (Complete Blood Count) with differential, Immature/Total ratio (I/T…
- Conditions
- Preterm Infant, Early-Onset Neonatal Sepsis, Umbilical Cord
- Trial name
- NCT03694613
- Testing
- Placental/Umbilical Cord Blood sample
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Lupus Nephritis
Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Prospective, multi-center, randomized, controlled, trial to compare tacrolimus with mycophenolate mofetil (MMF) for induces complete remission in lupus nephritis patients. The study duration is one year.
- Trial name
- NCT01580865
- Testing
- Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Ramathibodi Hospital
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab
- Trial name
- NIVO-ALCL (NCT03703050)
- Testing
- Nivolumab cohort 1, Nivolumab cohort 2
- Where
- 13 sites in Denmark, France and 1 more
- Volunteers
- 45 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Rectal Cancer
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy.
- Trial name
- NCT06719414
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer.
- Trial name
- NCT04781725
- Testing
- INT230-6, Saline injection
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Leukemia
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045422
- Testing
- recombinant interferon alfa, imatinib mesylate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Rectal Cancer
Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.
- Trial name
- NCT03238885
- Testing
- pelvic MR examination
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Sun Ying-Shi
Leukemia, Myeloid
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
It is often impossible to find therapeutic target in intermediate-risk AML, so it is very important to select appropriate chemotherapy protocol to eliminate minimal residual disease (MRD) in these AML patients.
- Trial name
- NCT03417427
- Testing
- Decitabine and Ara-C, Ara-C
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuejie Jiang
Sustained Virologic Response, Hepatitis B, Chronic
Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
In the treatment of chronic hepatitis B (CHB), viral suppression is closely related to disease progression, and the lower the viral load, the lower the risk of progression to cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- REACH (NCT04724785)
- Testing
- only monitoring, monitoring and regimen change if necessary, regimen change
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Pediatric Cancer
OmegaChild - Omega-3 Supplementation to Children Previously Treated for Cancer
The purpose of this study is to find an optimal dose of omega-3 that can be given to children who have completed cancer therapy.
- Trial name
- OmegaChild (NCT02134600)
- Testing
- Omega-3 enriched fruit juice
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Per Kogner
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Infection, Candida
Early Diagnosis of Candidiasis in Premature Infants
This observational study evaluated the performance of new lab tests in detecting candida species fungal infections in extremely low birth weight (ELBW) infants quickly and accurately.
- Conditions
- Infection, Candida, Candidiasis, Infant, Newborn
- Trial name
- Candida (NCT00109525)
- Where
- 20 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
Myelogenous Leukemia, Chronic, Chronic Phase
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission(CMR) while on…
- Trial name
- NCT01887561
- Testing
- dasatinib
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kanto CML Study Group
Upper Respiratory Infections
Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting
The purpose of this study is to assess the accuracy and ease-of-use of a simplified FilmArray Respiratory Panel test (FilmArray RP EZ) when performed according to the manufacturer's instructions by personnel in laboratories…
- Trial name
- NCT02232711
- Where
- 4 sites in United States
- Volunteers
- 1,082 people
- Sponsor
- BioFire Diagnostics, LLC